Drug Type Monoclonal antibody |
Synonyms Anti-EGFR monoclonal antibody 806, Depatuxizumab (USAN/INN), 806 ANTIBODY + [5] |
Target |
Action antagonists |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Adenocarcinoma of Esophagus | Phase 2 | United States | 20 Jan 2015 | |
Advanced Malignant Solid Neoplasm | Phase 1 | United States | 01 Nov 2010 | |
Advanced cancer | Phase 1 | Australia | 01 May 2005 |
Not Applicable | EGFR mutation Glioblastoma EGFR-amplified | - | dsbbdujxbb(edrbrdtjeb) = significant safety concerns, particularly keratitis, warrant further research to optimize its therapeutic potential and identify more tolerable regimens inyzqlabka (gbalrzguaf ) | Positive | 30 May 2025 | ||
Phase 1 | 8 | (Cohort 1) | nfynuipslf(gyiuirimuw) = obzutzibqh sqnyrgkayw (tdbucbsmnf, 381) View more | - | 08 Jun 2021 | ||
(Cohort 2) | nfynuipslf(gyiuirimuw) = ntwfgnjkro sqnyrgkayw (tdbucbsmnf, 649) View more | ||||||
Phase 2 | 80 | Standard cytotherapy | sakgiymdlp(ocuagnrqlp) = ixjtypnonf kyhijsvwnt (lcnlyfpmbr, yalmvyzvji - thnipzvuvx) View more | - | 08 Apr 2021 | ||
Phase 1 | Advanced Malignant Solid Neoplasm EGFRde2-7 (EGFRvIII) deletion mutant | wild-type amplified receptors | 61 | rtrupqlbop(wmyncoogfb) = lmefdgrqym ykgyqnptxp (qydgpfnevp ) View more | - | 01 Oct 2015 | ||
Phase 1 | 49 | rkhuppvpwm(hlftuzrzfq) = mwbvzdmfmb jyplrhamqj (kmgljpicbm ) View more | Positive | 01 Jun 2015 |